Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 80/100

Failure Rate

42.9%

3 terminated/withdrawn out of 7 trials

Success Rate

57.1%

-29.4% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

100%

4 of 4 completed trials have results

Key Signals

4 with results

Enrollment Performance

Analytics

Phase 2
5(71.4%)
Phase 1
2(28.6%)
7Total
Phase 2(5)
Phase 1(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (7)

Showing 7 of 7 trials
NCT03045328Phase 2Completed

Venetoclax and Ibrutinib in Patients With Relapsed/Refractory CLL or SLL

Role: lead

NCT00230334Phase 2Terminated

Phase II Gleevec Idiopathic Hypereosinophilic Syndrome

Role: lead

NCT02030405Phase 2Terminated

Ixazomib (MLN9708) in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia

Role: lead

NCT01550224Phase 2Completed

Temozolomide Plus Vorinostat in Relapse/Refractory Acute Myeloid Leukemia (AML)

Role: lead

NCT02635074Phase 1Terminated

Ibrutinib, Idarubicin and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia

Role: lead

NCT00230282Phase 2Completed

Phase 2 Fludarabine, Cytoxan and FCCAM <Alemtuzumab> in Untreated B-Cell Chronic Lymphocytic Leukemia

Role: lead

NCT00313079Phase 1Completed

Monoclonal Antibody (mAb) 216 With Chemotherapy in Adult Relapsed or Refractory B-Lineage Acute Lymphoblastic Leukemia

Role: lead

All 7 trials loaded